Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and
disease progression. Methods Clinical follow‐up was obtained 20 ± 3 months after [ 11 C]…

While considerable effort has focused on developing positron emission tomography β-amyloid
imaging radiotracers for the early diagnosis of Alzheimer's disease, no radiotracer is …

Amyloid imaging with 18 F-labeled radiotracers will allow widespread use, facilitating research,
diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study …

Neurofibrillary tangles in Alzheimer disease (AD) brains are composed of the microtubule-associated
protein tau. Noninvasive monitoring of tau protein aggregates in the living brain …

Non-invasive imaging of tau pathology in the living brain would be useful for accurately
diagnosing Alzheimer’s disease, tracking disease progression, and evaluating the treatment …

Purpose Diagnosis of tauopathies such as Alzheimer’s disease (AD) still relies on post-mortem
examination of the human brain. A non-invasive method of determining brain tau burden …

Purpose Amyloid imaging with 18 F-labelled radiotracers will allow widespread use of this
technique, facilitating research, diagnosis and therapeutic development for Alzheimer’s …

11 C-Pittsburgh compound-B ( 11 C-PiB) is the benchmark radiotracer for imaging of β-amyloid
(Aβ) plaque in Alzheimer disease (AD). F-labeled Aβ tracers subsequently developed for …

PET provides a noninvasive means to evaluate the functional integrity of the presynaptic
monoaminergic system in the living human brain. Methods: In this study, a novel 18 F-labeled …

Amyloid-β (Aβ) plaques are a pathological hallmark of Alzheimer's disease and a current
target for positron emission tomography (PET) imaging agents. Whilst [ 11 C]-PiB is currently …